Fyfe Gwen A. 4
4 · Cascadian Therapeutics, Inc. · Filed Mar 13, 2018
Insider Transaction Report
Form 4
Fyfe Gwen A.
Director
Transactions
- Disposition from Tender
Common Stock
2018-03-09−10,125→ 0 total - Disposition to Issuer
Restricted Stock Units
2018-03-09−13,927→ 0 total→ Common Stock (13,927 underlying)
Footnotes (4)
- [F1]Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
- [F2]Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
- [F3]The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.
- [F4]The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.